MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, Jennifer; P. Bogenschutz, Michael; Lilienstein, Alia; Harrison, Charlotte; E. Kleiman, Sarah; Parker-Guilbert, Kelly; Ot’alora G., Marcela; Garas, Wael; Paleos, Casey; Gorman, Ingmar; R. Nicholas, Christopher; C. Mithoefer, Michael; Carlin, Shannon; Poulter, Bruce; T. Mithoefer, Ann; Quevedo, Sylvestre; Beverly Wells, G.; Klaire, Sukhpreet; van der Kolk, Bessel; Tzarfaty, Keren; Amiaz, Revital; Worthy, Ray; Shannon, Scott; Woolley, Joshua; J. Marta, Cole; Gelfand, Yevgeniy; Hapke, Emma; Amar, Simon; Wallach, Yair; Brown, Randall; Hamilton, Scott; B. Wang, Julie; R. Coker, Allison; Matthews, Rebecca; de Boer, Alberdina; Yazar‐Klosinski, Berra; Emerson, Amy; Doblin, Rick

doi:10.1038/s41591-021-01336-3

Public

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Published in Nature Medicine • May 10, 2021

Authors:

Jennifer Mitchell

Michael P. Bogenschutz

Alia Lilienstein

Abstract

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3...

Subject

Placebo

MDMA

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!